RxDoctor Payments Data

Daniel Kapp, MD

Plastic Surgery · West Palm Beach, FLNPI 1235132416

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Organogenesis Inc. accounts for 87.7% of it on its own, with 37 other manufacturers making up the rest. 2025 is the largest year on record at $79,439, 4.8 times the $16,551 reported in 2019. Among plastic surgery clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$252,125in general payments, 2019–2025

Across 417 payments — averaging $604.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$221K
  • TELA Bio, Inc.$17K
  • AbbVie$5K
  • Davol Inc.$3K
  • Sientra, Inc.$1K
  • Integra Lifesciences Corporation$655
  • plus $4K from 32 others

What the payments were for

  • Consulting fees$129,58851%
  • Speaking & faculty fees$91,67636%
  • Travel & lodging$17,4667%
  • Food & beverage$13,3955%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$252,125 in reported general payments places this provider in the 95th percentile of 456 plastic surgery providers in Florida.

See all plastic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$844,971
Medicare patients
313
Services billed
2,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.13$6,527
Doxycycline Hyclate57$509
Cefadroxil50$360
Cyclobenzaprine Hcl17$119
Ciprofloxacin Hcl13$115
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim15$89
Mupirocin12$87
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$85
Ondansetron Hcl18$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$514$6,52713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 456 plastic surgery providers in Florida.

Other plastic surgery in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →